HIMS Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages HIMS Investors with Losses to Contact the Firm

A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making materially false statements about its privacy practices. The FTC accused HIMS of sharing customers' medical information with third-party advertisers including Meta and Snap, and charging consumers for prescriptions without proper consultation. The stock declined 14.73% on the news, dropping $4.32 per share to $25.00 on July 29, 2026.